financetom
Business
financetom
/
Business
/
Masimo smartwatches infringe Apple design patents, US jury says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Masimo smartwatches infringe Apple design patents, US jury says
Nov 3, 2024 12:04 PM

Oct 25 (Reuters) - Apple ( AAPL ) convinced a federal

jury on Friday that health monitoring tech company Masimo's ( MASI )

smartwatches infringe two of its design patents.

The jury, in Delaware, agreed with Apple ( AAPL ) that Masimo's ( MASI ) W1

and Freedom watches and chargers willfully violated Apple's ( AAPL )

patent rights in smartwatch designs, awarding the tech giant

$250 in damages. Apple's ( AAPL ) attorneys told the court the "ultimate

purpose" of its lawsuit was to win an injunction against sales

of Masimo's ( MASI ) smartwatches after an infringement ruling.

The jury also determined that Masimo's ( MASI ) watches did not

infringe Apple ( AAPL ) patents covering smartwatch inventions that the

tech giant had accused Masimo ( MASI ) of copying.

Masimo ( MASI ) said in a statement that the company appreciated the

jury's verdict "in favor of Masimo ( MASI ) and against Apple ( AAPL ) on nearly

all issues," and that the decision only applied to a

"discontinued module and charger."

"Apple ( AAPL ) primarily sought an injunction against Masimo's ( MASI )

current products, and the jury's verdict is a victory for Masimo ( MASI )

on that issue," Masimo ( MASI ) said.

Apple ( AAPL ) said in a statement that it was "glad the jury's

decision today will protect the innovations we advance on behalf

of our customers."

Irvine, California-based Masimo ( MASI ) accused Apple ( AAPL ) of hiring

away its employees and stealing its pulse oximetry technology

after discussing a potential collaboration. Masimo ( MASI ) convinced the

U.S. International Trade Commission last year to block imports

of Apple's ( AAPL ) Series 9 and Ultra 2 smartwatches after the

commission found that their technology for reading blood oxygen

levels infringed Masimo's ( MASI ) patents.

Apple ( AAPL ) has appealed the decision and resumed selling the

watches after removing the technology. The tech giant

countersued Masimo ( MASI ) for patent infringement in 2022, alleging

that Masimo ( MASI ) copied Apple Watch features to use in its

smartwatches.

Apple ( AAPL ) also accused Masimo ( MASI ) of using lawsuits at the ITC

and in California to "make way for Masimo's ( MASI ) own watch." Masimo ( MASI )

said Apple's ( AAPL ) patent lawsuit was "retaliatory" and "an attempt to

avoid the court in which the parties have been litigating their

dispute."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
GoldMining Up 2.6% In US Premarket As Reports Additional High-Grade Drilling Results and Identified Multiple Drill Targets, Sao Jorge Project, Brazil
GoldMining Up 2.6% In US Premarket As Reports Additional High-Grade Drilling Results and Identified Multiple Drill Targets, Sao Jorge Project, Brazil
Nov 11, 2024
07:36 AM EST, 11/11/2024 (MT Newswires) -- GoldMining Inc. ( GLDG ) was at last look up 2.6% in US premarket trade -- it was even higher -- as the company reported Monday additional assay results from the 2024 auger drilling program at its 100% owned Sao Jorge Project in the Tapajos gold district, Para State, Brazil. Among highlights, it...
Can-Fite BioPharma Doses First Patient in Namodenoson Phase 2a Trial in Pancreatic Cancer
Can-Fite BioPharma Doses First Patient in Namodenoson Phase 2a Trial in Pancreatic Cancer
Nov 11, 2024
07:33 AM EST, 11/11/2024 (MT Newswires) -- Can-Fite BioPharma ( CANF ) said Monday that the first patient has been dosed in its phase 2a trial of Namodenoson in patients with advanced pancreatic adenocarcinoma. The company said it targets to enroll about 20 evaluable patients in the trial. The study's primary objective is to characterize Namodenoson's safety profile, while the...
Cigna says it will not pursue combination with Humana
Cigna says it will not pursue combination with Humana
Nov 11, 2024
Nov 11 (Reuters) - Health insurer Cigna Group ( CI ) said on Monday it is not pursuing a combination with peer Humana . ...
TriSalus Life Sciences, Geo-Med Partner to Expand TriNav Infusion System Access in VA Medical Centers
TriSalus Life Sciences, Geo-Med Partner to Expand TriNav Infusion System Access in VA Medical Centers
Nov 11, 2024
07:36 AM EST, 11/11/2024 (MT Newswires) -- TriSalus Life Sciences ( TLSI ) said Monday that it has partnered with Geo-Med, a certified service-disabled veteran-owned small business, to expand the availability of its TriNav Infusion System across US Department of Veterans Affairs medical centers. The company said Geo-Med is a key supplier to the Veterans Affairs and the US Department...
Copyright 2023-2026 - www.financetom.com All Rights Reserved